
FcRn inhibitor demonstrates sustained IgG reduction in Phase I trial
Viridian Therapeutics has announced positive Phase I trial results for VRDN-008, a half-life extended bifunctional FcRn inhibitor licensed from Paragon Therapeutics. In the trial, VRDN-008 demonstrated a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile with the potential to be dosed every eight weeks. VRDN-008… Read More
